Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medivir AB's earnings per share without non-recurring items for the
three
months ended in Mar. 2026 was kr-0.02.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was kr-0.54.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 25.10% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was 7.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Medivir AB's EPS without NRI or its related term are showing as below:
OSTO:MVIR'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -51 Med: 15.5 Max: 118.5
Current: 25.1
During the past 13 years, Medivir AB's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 118.50% per year. The lowest was -51.00% per year. And the median was 15.50% per year.
OSTO:MVIR's 3-Year EPS without NRI Growth Rate is ranked better than 60.81% of 1166
companies
in the Biotechnology industry
Industry Median: 16.2
vs OSTO:MVIR: 25.10
Medivir AB's EPS (Diluted) for the
three
months ended in Mar. 2026 was kr-0.02.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was kr-0.54.
Medivir AB's EPS (Basic) for the
three
months ended in Mar. 2026 was kr-0.02.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was kr-0.54.
Medivir AB (OSTO:MVIR) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Medivir AB EPS without NRI Related Terms
Medivir AB EPS without NRI Historical Data
* Premium members only.
The historical data trend for Medivir AB's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:MVIR vs VRTX, REGN, RVMD: EPS without NRI Comparison
For the Biotechnology subindustry, Medivir AB's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medivir AB PE Ratio without NRI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medivir AB's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Medivir AB's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.54
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medivir AB (OSTO:MVIR) has a EPS without NRI of kr-0.54 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Medivir AB and its competitors. According to the industry distribution chart, Medivir AB ranks #457 out of 1166 companies in the Biotechnology industry, placing it in the top 39.2%.
Is Medivir AB's EPS without NRI too high?
Medivir AB's current EPS without NRI is kr-0.54. Based on the distribution chart, Medivir AB ranks #457 out of 1166 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Medivir AB has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medivir AB's EPS without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medivir AB ranks #457 out of 1166 companies for EPS without NRI. This puts Medivir AB in the upper half of its industry. The industry median EPS without NRI is 16.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.20, based on 1,166 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Medivir AB and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medivir AB's current EPS without NRI is kr-0.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medivir AB stock overvalued right now?
Based on GuruFocus' analysis, Medivir AB (OSTO:MVIR) is currently considered Significantly Overvalued. The stock's GF Value™ is kr1.11, compared to a current price of kr1.80 — trading 62.2% above its estimated fair value. The current EPS without NRI is kr-0.54. Medivir AB's overall GF Score™ is 50/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Medivir AB (OSTO:MVIR), the current EPS without NRI is kr-0.54 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medivir AB (OSTO:MVIR) Overvalued in 2026?
Based on GuruFocus' analysis, Medivir AB stock appears to be overvalued.
The current stock price of kr1.80 is trading 62.2% above its estimated GF Value™ of kr1.11.
GuruFocus considers Medivir AB to be Significantly Overvalued.
Key valuation signals for OSTO:MVIR:
EPS without NRI: kr-0.54
GF Value™: kr1.11 vs. price of kr1.80 (62.2% above fair value)
No single metric tells the full story. See the OSTO:MVIR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication that selectively delivers the cell-killing agent to the tumor while minimizing potentially harmful effects on normal cells. It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. Medivir also also has four out-licensed projects Xerclear, MIV-701, MBLI/MET-X. Geographically, it generates its maximum revenue from Europe and other regions.
50GF Score
Get the complete analysis for OSTO:MVIR
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:MVIR has been successfully added to your 
